Vir Biotechnology
119 hedge funds and large institutions have $2.41B invested in Vir Biotechnology in 2020 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 27 closing their positions.
694% more capital inflows, than outflows
Capital inflows: $819M | Capital outflows: $103M
118% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 22
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
9.73% more ownership
Funds ownership: 45.4% → 55.14% (+9.7%)
6% more funds holding
Funds holding: 112 → 119 (+7)
2% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $5.6M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$439M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$223M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.6M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$18.8M |
| 5 |
Goldman Sachs
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$38.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$25.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$7.47M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.04M |
VIR Hedge Fund Activity: Q3 2020 in Review
119 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2020, worth a combined $2.41B — up 9.7% from $2.19B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new VIR positions and 27 closed out — a net gain of 7 holders — while 48 added to existing stakes and 22 trimmed.
The largest buyer was Capital International Investors, adding an estimated $439M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $38.9M sold.
- 119 institutional investors held Vir Biotechnology (VIR) as of Q3 2020, up from 112 in Q2 2020.
- Funds reported $2.41B of Vir Biotechnology stock for Q3 2020, up 9.7% quarter-over-quarter.
- 34 funds opened new Vir Biotechnology positions in Q3 2020 and 27 closed out, a net change of +7 holders.
- The largest Vir Biotechnology buyer in Q3 2020 was Capital International Investors, an estimated $439M added.
- The largest Vir Biotechnology seller in Q3 2020 was Janus Henderson Group, an estimated $38.9M sold.
Based on aggregated 13F filings for Q3 2020.